Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Yamanouchi Will Promote Vesicare With 150 Specialty Sales Reps

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA clears Vesicare for the treatment of overactive bladder. Yamanouchi and co-promotion partner GlaxoSmithKline will launch solifenacin in January 2005, with GSK sales reps handling primary care duties and Yamanouchi reps detailing to urologist and ob/gyns.

You may also be interested in...



Novartis' Enablex For Overactive Bladder Clears FDA

Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.

Novartis' Enablex For Overactive Bladder Clears FDA

Enablex will enter a crowded overactive bladder market in early 2005 that includes two recent entrants, Yamanouchi/GlaxoSmithKline's Vesicare and Indevus/Pliva's Sanctura. Novartis may emphasize darifenacin's "unique" action on the M3 receptor to distinguish it from competitors.

Sanctura Accounts For 7.6% Of New Overactive Bladder Scripts By Urologists

Indevus/Pliva's overactive bladder product has gained 3% of new scripts overall since its August launch. Indevus plans to begin Phase III trials of Sanctura XR in mid-2005.

Related Content

Topics

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel